ATAI
was well tolerated with no dose limiting toxicities identified up to the highest dose of given every hours for days there were no serious adverse events reported nor discontinuations due to adverse events and both single and multiple ascending dose sad and mad regimens showed only mild adverse events that were comparable to placebo treated subjects no evidence of sedation or other side effects at any doses tested dose dependent increase in frontal beta power was demonstrated in subjects receiving but not with placebo providing evidence of target engagement and mechanism of action these results show potential use for as a clinically superior treatment for generalized anxiety disorder gad compared to and combination pharmacodynamic effect along lower incidence severity shows favorable profile | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
32 of 41
Related slides by other companies
Kymera
Investor Presentation
November 2023
adverse events related to occurring in patient | Kymera
D-Wave
Investor Day
January 2024
auto scheduling process food group | D-Wave
DICE Therapeutics
Investor Presentation
March 2023
demonstrated a favorable safety and tolerability profile | DICE Therapeutics
Kymera
Investor Presentation
December 2023
adverse events related to occurring in patient | Kymera
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io